Applied Therapeutics, Inc. (APLT)

Applied Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.46	9.99	-	-	-
Revenue Growth (YoY)	-95.45%	-	-	-	-
Cost of Revenue	48.74	53.91	55.63	-	-
Gross Profit	-48.29	-43.91	-55.63	-	-
Selling, General & Admin	56.01	20.62	27.32	43.05	32.68
Research & Development	-	-	-	62.57	61.79
Operating Expenses	56.01	20.62	27.32	105.62	94.47
Operating Income	-104.3	-64.54	-82.95	-105.62	-94.47
Interest & Investment Income	3.53	1.37	0.69	0.56	0.56
Other Non Operating Income (Expenses)	-4.78	-56.57	-0.07	-	-
EBT Excluding Unusual Items	-105.55	-119.74	-82.33	-105.06	-93.91
Gain (Loss) on Sale of Investments	-0.08	-0.03	-0.18	-0.52	-0.05
Pretax Income	-105.62	-119.76	-82.51	-105.58	-93.96
Net Income	-105.62	-119.76	-82.51	-105.58	-93.96
Net Income to Common	-105.62	-119.76	-82.51	-105.58	-93.96
Shares Outstanding (Basic)	140	84	38	26	22
Shares Outstanding (Diluted)	140	84	38	26	22
Shares Change (YoY)	65.63%	122.72%	47.77%	16.53%	71.19%
EPS (Basic)	-0.76	-1.42	-2.18	-4.12	-4.28
EPS (Diluted)	-0.76	-1.42	-2.18	-4.12	-4.28
Operating Margin	-22922.86%	-645.80%	-	-	-
Profit Margin	-23214.07%	-1198.47%	-	-	-
EBITDA	-104.3	-64.53	-82.95	-105.62	-
D&A For EBITDA	0	0	0	0	-
EBIT	-104.3	-64.54	-82.95	-105.62	-94.47
Revenue as Reported	0.46	9.99	-	-	-

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q